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Abstract  
Hereditary hemorrhagic telangectasia (HHT) or Rendu-Osler-Weber syndrome, is a rare genetic 
disorder with autosomal dominance and variable penetrance. The typical findings of the disease are 
telangiectasias in skin and mucous membranes, and arteriovenous malformations presenting in the 
organs like lung, intestine, brain and liver. It is characterized by the classic triad of recurrent 
epistaxis, mucocutaneous telangiectasias and visceral hemorrhages, with familial occurrence.  
This article describes a case of HHT of an adult patient, associated with multiple angiodysplasic 
injuries in the nasal mucosa, upper gastrointestinal tract, lungs and who presents continuous blood 
loss, resulting iron deficiency anemia. Based on clinical and diagnostic findings, we diagnosed this 
case as HHT, which has rarely been reported in our literature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Manifestations of the hereditary hemorrhagic 
telangiectasia (HHT) were first described in 1896, 
when Henri Jules Louis Rendu described for the first 
time the classical picture of HHT as a disease of 
mucocutaneous telangiectasias, epistaxis, and familial 
nature. The following decade brought accurate case 
descriptions of the disease by William Osler (1900) 
and Frederick Parkes Weber (1907), so the eponym 
“Rendu-Osler-Weber” was created [1].  
Although the first description was made more 
than a century ago, only in the last decade the real 
confirmation of the genetic origin of disease has been 
proven. HHT is a disorder with autosomal dominant 
inheritance and variable penetrance, although in some 
the cases there is no family history and they could 
represent sporadic mutations [2, 3]. HHT also exhibits 
the property of “incomplete penetrance”, an inability to 
express the full spectrum of disease phenotype, 
despite carrying a defective gene [4]. In earlier studies 
the prevalence of the disease was estimated at 1 in 
100,000, however, HHT prevalence nowadays is more 
frequent than formerly thought [5, 6]. The vascular 
malformations in HHT consist of direct arteriovenous 
connections through thinwalled aneurysms, and range 
from small telangiectases (predominantly mucosal, 
skin, and visceral) to larger visceral arteriovenous 
malformations (AVM) [6]. Most clinical complications 
of the disease are related to pulmonary AVM (PAVM) 
about 30-60% [4, 7, 8]. It is estimated that 11-40% of 
HHT patients have gastrointestinal, 8-16% hepatic, 
and 5-11% cerebral involvement [1, 9]. Epistaxis is 
usually the first manifestation up to 90% of the 
patients [5, 6].  
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The present study describes a typical case of 
HHT of a 47-year-old female, which is manifested by 
recurrent epistaxis, multiple angiodysplasic injuries 
presenting in the organs and had been suffering from 
iron deficiency anemia. 
 
Case report 
A 47-year-old woman had a history of 
admissions to the Department of Hematology, Clinical 
Center Kragujevac, due to recurrent mild 
manifestations of iron deficiency anemia from 1991 to 
2011. The clinical description of the patient reveals 
that the frequency of hospitalization increased in the 
last two years decurrent of the persistence of anemia. 
Despite a high-dose oral iron replacement regimen, 
her hemoglobin levels did not reach normal values. 
She continued to present sporadic episodes of 
dyspnea, hypotension, tachycardia, headaches, 
weight loss, which had been observed without any 
medical intervention. In December of 2011, the patient 
invariably presenting with these symptoms, followed 
by low hemoglobin level 47 (116-154 g/L), and 
decresed levels of hematocrit 0.2 (0.345-0.463 L/L), 
ferritin 12 (20-300 g/L), serum iron 2.5 (6.6-26 
mol/L) and platelet count 76 (158.7-387.7 x 10
9
/L). 
Blood laboratory findings demonstrated severe iron 
deficiency anemia.  
 
Figure 1: Radionuclide ventilation/perfusion lung (V/P) scanning, 
using radiopharmaceuticals 99mTc-DTPA*(aerosol)/ 99mTc-MAA†; 
* diethylenetriaminepentaacetic acid (DTPA) labelled with meta-
stable nuclear isotope of technetium-99; † macro aggregates of 
human albumin (MAA), labelled with metastable nuclear isotope of 
technetium-99. 
 
She was admitted to hematology clinic and 
instituted therapeutical support under demand. Patient 
has been treated with blood transfusions and getting 
hemodynamic stabilization after the treatment 
replacement with concentrated erythrocytes. Other 
laboratory work-up was normal, including normal 
coagulation profile and stool occult blood test (Adler-
Weber). Although there was no clear history of low 
dietary intake of iron, evaluation for a source of 
bleeding or a malabsorptive process was initiated. 
During her cutaneous examination, at ear-nose-throat 
clinic, pallor and discoloration in the oral mucosa and 
tongue was noticed without any telangiectasias.  
Anterior rhinoscopy revealed haematic dots and 
crusts on septal mucosa.  
 
Figure 2: Multisliced computed tomography (MDCT) of the chest 
(coronal section) in lung parenchyma invert window, show sharply 
defined lobulated soft tissue mass of uniform density in the lower 
lobe of the right lung. 
 
Endoscopy of the upper digestive tract was 
performed. The results of the endoscopy indicated 
multiple gastric angiodysplasias of the fundus and 
body of the stomach and paraesophageal hiatus 
hernia as well.  Fiberoptic rectosigmoidoscopy 
disclosed any angiodysplasic injuries in the superior 
and medial portions. The routine chest radiograph 
revealed a defined lobulated area of uniform density in 
the lower lobe of the right lung. The patient was 
submitted to ventilation-perfusion (V/P) scintigraphy. 
Images that were obtained, in SPECT modality, 
revealed non-segmental perfusion defects in the lower 
right hemitorax with corresponding defects in the 
ventilation scan (Figure 1). Although there was no 
evidence of “ventilation–perfusion mismatch”, the 
diagnosis of pulmonary embolism was ruled out, but 
may provide evidence of other pathologies, like 
neoplasma or PAVM. Regarding all previous aspects, 
we assumed the existence of PAVM.  
Next, multislice computed tomography 
(MDCT) of the chest was indicated. The lesions on the 
MDCT chest were identified as subpleural, nodular, 
lobulated mass (35 x 30mm) of uniform density in the 
right lower lobe anteriorly (Figure 2), with a single 
feeding artery and a draining vein, consistent with 
PAVM (Figure 3). Computed tomographic (CT) study 
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of the skull did not found evidence of AVMs, although 
it revealed a small area of supratentorial subcortical 
calcification.  
 
Figure 3: Multisliced computed tomography (MDCT) of the chest 
(axial section) in soft tissue window, showing lobulated mass of 
uniform density in the right lower lobe anteriorly, with a single 
feeding artery and a draining vein. 
 
Discussion 
The prevalence of HHT was estimated at 1–2 
in 100,000, with a regional variations, homogeneous 
race and gender distribution, and areas of high 
prevalence such as in the Netherlands Antilles 
(1:1,331), in the Danish island Funen (1:3,500), in 
Vermont USA (1:16,500), and in northern England 
(1:39,216) [8, 10]. From a genetic standpoint, average 
prevalence is more frequent (about 1:10,000) 
characterized by incomplete penetrance [4-6].  
The term "hereditary hemorrhagic 
telangiectasia" was first used in 1909 [6], but the real 
confirmation of the genetic origin of disease has been 
only proven a century later. HHT represents 
autosomal dominant disease, caused by mutations in 
one of two genes that have led to its subclassification 
into types HHT1 and HHT2 [11]. Type 2 is more 
frequent.  
Genes, endoglin on chromosome 9q34 and 
the activin receptor-like kinase 1 on chromosome 
12q13 [4, 12], encode for transmembrane proteins 
involved in the transforming growth factor (TGF)-β 
signalling pathway. Expressed genes are 
predominantly on vascular endothelium [3], and may 
explain abnormalities in vasculogenesis and 
angiogenesis [13, 14]. Additionally, a HHT type 3 has 
been described [2]. At least two more loci (and yet 
unidentified genes) seem to be involved in patients 
with HHT [2, 13, 15].  
The exact pathologic mechanisms that 
underlie HHT pathogenesis remain obscure, though 
they are presumably a result of genomic mutations. 
The development of a cutaneous telangiectasia is a 
progressive process. In the early stage a focal 
dilatation develops, and in a more advanced stage the 
venules, arterioles and their branches are markedly 
dilated. Such dilation makes the capillaries disappear 
after some time, causing the arteriovenous 
malformations [4, 12]. 
Data from the personal history of the patient 
revealed repeated episodes of nasal bleeding of 
unknown cause, multiple episodes of reccurent 
palpitations, a fatigue, dizziness in recent decades but 
without physician's involvement. These abnormalities 
have been described in the literature, according to 
which, by the age of 16 years, 71% of affected 
individuals develop some sign of HHT, rising to over 
90% by the age of 40 years [10]. Recidivant 
nosebleed, result from telangiectasia of the nasal 
mucosa, is the most common clinical characteristic of 
HHT, up to 90% during infancy, and are often 
misdiagnosed [11]. Other clinical finding of small 
mucosal and skin telangiectasias is present at 13-89% 
[11]. Our patient’s disease severity varied from severe 
to such mild manifestations, that the disease is never 
suspected. Only when the routine chest radiograph 
revealed a soft tissue mass in the lower lobe of the 
right lung, which was confirmed, after V-P scan and 
chest MDCT, as PAVM. According to recent studies, 
the incidence of the PAVM was estimated up to 50-
60% of persons with HHT [15, 16]. PAVM aappear in 
both lungs, having a predilection for the lower 
pulmonary lobes, rather multiple [35–65%] than 
solitary [6]. Such case was at our patient too.  PAVM 
are mostly without hemodynamic or hematological 
alterations during infancy [7].  Symptoms start around 
the second decade of life and may include cyanosis 
(18%), hemoptysis (10%) and chest pain (6%) [15]. 
These conditions, which may lead to hypoxemia, 
dyspnea and especially iron deficiency anemia, are 
often clinically misdiagnosed [10]. Possibly severe or 
lethal hemorrhagic complications have been 
described in about 7% patients with HHT and PAVM, 
including intrabronchial or intrapleural rupture of 
PAVM with ensuing hemoptysis or hemothorax [15]. 
PAVM also result in direct right to left shunts, so the 
absence of a filltering capillary bed, allow embolism to 
reach the systemic arteries and can lead to neurologic 
complications including transient ischemic attack, 
cerebral stroke and cerebral abscess [16, 18]. 
Cerebral involvement of HHT occurs in 5–11% of 
patients with HHT [9]. Investigations using CT of the 
patient’s skull didn’t found evidence of AVM, but 
calcification was noted which can lead to minor 
intracranial hemorrhage. Gastrointestinal (GI) AVM 
occurs in 11-40% of the patients, and can lead to GI 
bleedings, and are more commonly situated in the 
stomach or duodenum than in the colon [6, 16, 18]. 
We also detected angiodysplasias in the bulbus and 
the duodenum of the patient. Multiple episodes of iron 
deficiency anemia at our patient could be a result of 
intermittent GI hemorrhage. Fiberoptic rectosigmo-
idoscopy didn’t reveal any angiodysplasic injuries, and 
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stool occult blood was also negative. Hepatic 
involvement is rare, present in 8%-16% of the patients 
with HHT [14, 18], including portal hypertension and 
hepatocellular insufficiency [5, 6, 8].  
HHT is increasingly diagnosed in children 
especially since genetic testing has been made 
available [3, 7, 15]. All persons with a family history of 
HHT should undergo genetic screening, because 
about 12% of those affected may develop clinical 
symptoms [3]. Owing to the lack of genetic diagnosis 
in routine clinical practice, initial diagnosis should rely 
on the targeted physical examination, especially for its 
potential for associated morbidity. The manifestations 
may not be present at birth, but develop with 
increasing age [10, 11] Due to late onset penetrance, 
the diagnosis is usually missed. Diagnosis is based on 
the four components of the “Curaçao” criteria, 
established by the Scientific Advisory Board of the 
HHT Foundation International, Inc. (Table 1) [12, 19]. 
The current clinical diagnosis of HHT requires that at 
least 3 out of 4 criteria should be fulfilled in order to 
confirm the diagnosis. Our case met three of four 
criteria: recurrent epistaxis, telangiectasias, GI 
bleeding combined with anemia. Assessment of the 
family history was unobtainable, because family 
information was unclear and without any medical 
record.  
Table 1: Diagnostic criteria for the diagnosis of HHT (Curaçao 
criteria). 
 
 
The current diagnostic approach includes CT 
scan which is now the gold standard for the diagnosis 
of AVM. Chest CT-scan, especially with intravenous 
injection of contrast medium, enables the differential 
diagnosis of PAVM from other nodules and 
assessment of perfusion [20]. Pulmonary angiography 
is usually used for transcatheter treatment, and for 
CNS involvement magnetic resonance imaging is the 
best diagnostic method [7, 8]. Pulse oximetry with 
arterial blood gas analysis and V/P scan are not 
widely in use, however, V/P scan can be useful for 
quantifying a shunt fraction in a patient with PAVM 
[21].  From these findings, the diagnosis of hereditary 
hemorrhagic telangiectasia, at our patient, was made.  
Therapeutic approach is of palliative nature 
only and helps prevent complications. There still is no 
consensus on the best treatment option, so 
multidisciplinary collaborative approach is required [1, 
23]. In patients with epistaxis, multiple approaches 
have been tried, including electrocautery, septo-
dermoplasty, embolization [6, 9]. In recent years, the 
process of catheter embolization for PAVMs and GI 
bleeding has been enforced, although there are still 
no studies regarding the long term follow up of these 
patients [22]. Hepatic AVM’s are currently treated only 
if patient show a signs of liver and heart failure [5,8]. 
New therapy approaches is now available including 
thalidomide and a recombinant, humanized, 
monoclonal antibody Bevacizumab. Although the 
overall outlook is promising, the real efficacy of these 
treatment approaches still needs further evaluation 
[23, 24].  
In conclusion, more than once in this study, 
we emphasized that greater clinical awareness may 
be the first step to identify patients with HHT, and may 
play a key role in the timely referral of these patients. 
Unfortunately, as is the case at our patient, clinical 
manifestations are often under-recognized and the 
diagnosis and treatment are frequently delayed for 
many years, even decades. Thus, it is fundamentally 
important that the physician be up to date to the 
disease’s etiopathogenesis to perform correct 
diagnosis, alter the clinical course and affect the 
outcome. In the management of the disease, 
especially in high-risk individuals, it is advised to 
suspect presence of the most serious complications 
such as PAVM, respiratory distress and lethal 
hemorrhagic complications. 
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